文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在一大群系统性硬化症相关间质性肺病患者中评估启动子变异体。

Assessing the promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease.

作者信息

Rosa-Baez Carlos, Rangel-Pelaez Carlos, Rodriguez-Martin Inmaculada, Kerick Martin, Guillen-Del-Castillo Alfredo, Simeon-Aznar Carmen P, Callejas José Luis, Voskuyl Alexandre E, Kreuter Alexander, Distler Oliver, Proudman Susanna M, Nikpour Mandana, Hunzelmann Nicolas, De Vries-Bouwstra Jeska K, Herrick Ariane L, Allanore Yannick, Beretta Lorenzo, Mayes Maureen D, Denton Christopher P, Assassi Shervin, Martin Javier, Acosta-Herrera Marialbert

机构信息

Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC, Granada, Spain.

Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

出版信息

RMD Open. 2025 Aug 12;11(3):e005754. doi: 10.1136/rmdopen-2025-005754.


DOI:10.1136/rmdopen-2025-005754
PMID:40803819
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12352244/
Abstract

OBJECTIVE: The common gain-of-function variant rs35705950, located in the promoter of gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date. METHODS: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls. RESULTS: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance. CONCLUSION: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.

摘要

目的:位于基因启动子区域的常见功能获得性变异rs35705950与不同病因的间质性肺疾病(ILDs)密切相关,如特发性肺纤维化(IPF)和类风湿关节炎相关的ILD(RA-ILD)。在本研究中,我们旨在调查该变异及其附近的单核苷酸多态性(SNPs)在迄今为止最大的系统性硬化症相关ILD(SSc-ILD)队列中的相关性。 方法:从血液/唾液中采集样本,随后进行DNA提取,并使用SNP阵列进行基因分型。使用基因组推算获得rs35705950以及100 Kb内另外903个变异的数据。随后,我们在荟萃分析中测试它们的相关性,以提高结果的一致性,该分析包括10个欧洲血统队列,其中有2363例SSc-ILD患者、3526例无ILD的SSc患者和15076例对照。 结果:荟萃分析显示,rs35705950与SSc-ILD之间无显著相关性,无论是比较有ILD和无ILD的SSc患者(p值:0.588,OR:1.05,95% CI:0.87至1.27),还是比较SSc-ILD患者与对照(p值:0.061,OR:1.16,95% CI:0.99至1.36)。此外,在基因组区域测试的另外903个变异均未达到统计学显著性。 结论:尽管分析了迄今为止最大且统计学效力最强的SSc-ILD队列,但我们未发现基因启动子变异rs35705950及其周围的SNPs与SSc-ILD之间存在关联的证据。这些结果表明,SSc-ILD的致病机制可能仅部分与其他类似ILD(如IPF或RA-ILD)的致病机制重叠。这凸显了对其遗传结构进行进一步研究的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67ce/12352244/2ea216bee1e9/rmdopen-11-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67ce/12352244/2ea216bee1e9/rmdopen-11-3-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67ce/12352244/2ea216bee1e9/rmdopen-11-3-g001.jpg

相似文献

[1]
Assessing the promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease.

RMD Open. 2025-8-12

[2]
FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease.

Rheumatology (Oxford). 2024-10-17

[3]
Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis.

Mol Med. 2025-2-20

[4]
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.

Cochrane Database Syst Rev. 2018-1-3

[5]
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.

Ther Adv Respir Dis. 2025

[6]
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study.

Lancet Rheumatol. 2025-7

[7]
Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics.

Arthritis Res Ther. 2025-7-10

[8]
An exploratory analysis of differences in serum protein expression by sex in patients with systemic sclerosis associated interstitial lung disease.

BMC Pulm Med. 2025-1-13

[9]
Association of the promoter polymorphism with idiopathic pulmonary fibrosis in a lebanese cohort.

Front Genet. 2025-6-24

[10]
Prescription of Controlled Substances: Benefits and Risks

2025-1

本文引用的文献

[1]
FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease.

Rheumatology (Oxford). 2024-10-17

[2]
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.

Nat Rev Rheumatol. 2024-1

[3]
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Clin Exp Rheumatol. 2022-2

[4]
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).

Ann Rheum Dis. 2021-2

[5]
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.

Semin Arthritis Rheum. 2020-10

[6]
Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing.

ERJ Open Res. 2019-6-10

[7]
Role of imaging in progressive-fibrosing interstitial lung diseases.

Eur Respir Rev. 2018-12-21

[8]
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

N Engl J Med. 2018-10-20

[9]
Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis.

Respir Med. 2017-7-17

[10]
Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Eur Respir J. 2017-5-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索